Actinogen is developing a revolutionary oral therapeutic, Xanamem^®, which controls levels of the “stress hormone” cortisol in the brain, with the goal of improving the lives of patients and their families. Topline results from our first pivotal Alzheimer’s trial, evaluating its potential to slow disease progression, are expected in November 2026.

2026 AGM - Letter to Shareholders, Notice of AGM & Proxy Form

ACW has issued documents for its Annual General Meeting to be held on Monday 30 November 2026 at 10am. This will be a hybrid meeting to be held in Sydney and online. Shareholders should check emails or post (depeding on preferences) for details and proxy voting instructions.

View AGM details and documents on the ACW InvestorHub

ACW receives $10.8m R&D tax incentive rebate from the ATO

Actionogen has received a research and development tax incentive (RDTI) rebate of $10.8m from the ATO for the 2026 financial year.
After repaying loans advanced against this FY26 RDTI, the net proceeds received were ~$6.0m.

ACW pivotal Alzheimers trial database lock - results mid-Nov

Actinogen has announced formal achievement of the ‘database lock’ milestone in its XanaMIA phase 2b/3 Alzheimer’s disease trial. Guidance for trial topline final results readout has been narrowed to mid-November this year.

ACW September 2026 quarterly activity report & Appendix 4C

Actinogen has released its quarterly activity report and Appendix 4C for the three-month period ended 30 September 2026.

XanaMIA pivotal Alzheimer's disease trial completes final patient visit

Actinogen has announced that the final trial participant visit has been completed in its XanaMIA phase 2b/3 Alzheimer’s disease clinical trial. The topline final results readout for the trial remains on track for November this year.

Xanamem oral presentation at 6th International Conference on Cognitive and Behavioral Neurosciences in Paris

ACW CMO, Dr Dana Hilt, presented the latest insights on Xanamem at the 6th International Conference on Cognitive and Behavioral Neurosciences in Paris, highlighting its potential as a novel treatment for neuropsychiatric and neurodegenerative disorders.

FY 2026 financial results - pivotal Alzheimer’s trial results imminent